The state squeezed the price of medicines and then squeezed the "moisture" of these commonly used medicines to cut the "floor price"

On the 3rd, the fourth batch of national drug collection, which has attracted much attention, announced the results of the proposed winning drug, with an average price reduction of 52%.
noteworthy that in this round of harvesting, there has been a significant increase in the variety of injections, as well as drugs for the treatment of mental illness.
in the eyes of industry experts, the future of domestic high-end generic drugs to replace the original research drug market process will accelerate, at the same time, domestic pharmaceutical companies are also facing more intense competition for innovative technology, as well as industry reshuffle integration.
collection of drug prices and then "diving" antidepressants into the proposed drug prices significantly "diving" is still the most concerned about the highlights of this collection.
all 45 drugs included in the procurement were successful, with an average price reduction of 52 per cent.
this batch collection, many anti-cancer drug prices directly "waist cut."
, for example, the price of the anti-cancer drug soraphinist dropped from 95 yuan to 30 yuan, according to the daily dose of 2 tablets, can save patients 3900 yuan per month.
the price of the anti-cancer drug boron titezami injections for the treatment of multiple myeloma was reduced from 1500 yuan to 600 yuan, saving about 36,000 yuan for the entire course of treatment.
addition, the stomach ulcer treatment drug Esomeprazole intestinal tablets (20mg / tablet), after the collection of each piece from 9 yuan to 3 yuan, the entire course of treatment can save about 240 yuan.
it is worth mentioning that this collection for the first time included a number of injection varieties, including 8 injection varieties, more than the sum of the first three batches, the collection coverage drug dosage form category further expanded.
8 varieties accounted for 31% of the total amount of medicines purchased, with an average price reduction of 75%.
to clinically widely used ammonia hydrochloride injection as an example, Yunnan Longhai Natural Plant Pharmaceutical Co., Ltd. products of the proposed selection price is only 2.3 yuan, the average price of one is only more than 2 mao.
injections are widely used in clinical practice, the dosage is large, and the inclusion of multiple injectable products in the collection has been reduced, which means that the national collection is further expanding its coverage.
addition, this procurement involves drugs in the field of treatment such as hypertension, diabetes, digestive tract diseases, malignant tumors, etc., as well as psychotic drugs, including antidepressants.
For example, for the treatment of depression and widespread anxiety disorders of hydrochloric acid Lositin intestinal capsules, this collection has a number of domestic pharmaceutical companies of generic products into the procurement, including Qingdao Baiyang Pharmaceutical Co., Ltd., Shanghai Shanghai Pharmaceutical Co., Ltd., Shi Pharmaceutical Group, Ohyi Pharmaceutical Co., Ltd.
generic drugs to accelerate the replacement of the original drug prices in addition to more innovative information from the State Health Insurance Administration shows that a total of 152 enterprises participated in this collection, resulting in 118 enterprises to be selected, enterprises to increase the proportion of the proposed selection to 71%.
is worth noting that in this collection, some multinational pharmaceutical companies have also changed the "Buddhist" attitude, positive quotations.
158 proposed products include 5 products from 5 foreign-funded enterprises, involving multinational pharmaceutical companies in Germany, France, India and Japan.
, for example, Fessen Yuscabi's propofol medium/long-chain fat milk injections and Sanofi's ammonia pills have both been reduced by more than 80 per cent, outscaleing local pharmaceutical companies.
other hand, with the multi-round collection landing, generic drugs accelerated replacement of the original research drug competition pattern is becoming more and more prominent.
158 of the 158 products to be selected, including 156 generics evaluated for consistency of quality and efficacy, and 2 original drugs.
generics account for an absolute proportion.
industry analysis, the main market share of some varieties by the original research drugs occupied, domestic pharmaceutical companies can use the collection of generic drugs to quickly seize market share.
the same time, with the continuous promotion of consistent evaluation, collection will become a generic drug sales model, and with the lower price of products, drug access is further improved, the speed of product release greatly increased.
the background of increasingly fierce competition in domestic generic drugs, in addition to price, technological innovation is also the key focus of the survival of the fittest competition of pharmaceutical companies.
E.g., Baiyang Pharmaceutical General Manager Zheng Aiju on the media, the enterprise in this selected collection of hydrochloric acid Loxitin intestinal capsules using intestinally soluble micro-pill wrapping process (including the pharmaceutical layer, isolation layer, intestinal solute layer), the production process is complex, the drug preparation technology has a very big challenge, high-end generic technology competition.
the country to "squeeze water" should be picked into the inevitable trend of "group purchase", "soul cut price", the state shot "squeezed water" ... Public opinion often describes the concentration of drug procurement.
Indeed, from the "4 plus 7" collection pilot to the national expansion, the two years of national "group purchase" drugs brought breakthrough results: three batches of national collection of a total of 112 drugs, an average price reduction of 54%, saving costs overall more than 100 billion yuan.
the results of the selection, the General Office of the State Council has just issued the Opinions on Promoting the Normal Institutionalization of the Purchase of Drug Concentrated Bands.
It is clearly stated that, in accordance with the principle of basic and clinical protection, the focus will be on the basic medical insurance drug catalog of large quantities of drugs, high procurement amount of drugs into the procurement scope, and gradually cover the domestic market clinically necessary, reliable quality of all types of drugs, so that should be harvested.
addition, the document emphasizes that priority is given to the procurement of medicines that are evaluated for consistency of quality and efficacy of generic drugs (including the same as between) and the following.
quantity or amount of qualified drugs, i.e. to initiate centralized strip procurement.
actively explore the appropriate procurement methods for "orphan medicine" and shortage of medicines to promote the stability of supply.
means that in the future, the inclusion of more types and therapeutic drugs in national drug collection is a foreche, and the public's "drug price list" options will continue to expand.
and for pharmaceutical companies, especially for domestic generics companies, collection is more like a watershed in the reshuffle of the industry.
China Pharmaceutical Business Association Vice President Fu Gang to the media analysis, if it is generic drugs, the original did not have a certain market size, the enterprise itself has no international layout, domestic collection and no winning bid, in the hospital there is no such opportunity to be the first patient prescription, enterprise development will be more difficult.
" thousands of pharmaceutical companies this decentralized pattern, the industry is also immature performance, there will be an integration process.
" pay steel analysis, domestic generic drug companies will experience "merger of similar items", some powerful enterprises to win, the industry gradually matured, which is beneficial to market supervision and industrial ecology.